{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:56:28Z","timestamp":1770980188242,"version":"3.50.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Aims and objectives<\/jats:title>\n                    <jats:p>To evaluate a study design aimed to assess the effectiveness and safety of IV paracetamol compared to IV ibuprofen for rescue treatment of clinically and hsPDA in preterm infants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>This pilot randomised controlled trial was conducted in the regional neonatal intensive care unit in Manchester, UK, between September 2021 and August 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>The study recruited preterm infants (gestational age &amp;lt;32 weeks or birth weight &amp;lt;1,500\u2005g) diagnosed with hsPDA via echocardiogram and presenting with signs and symptoms of PDA. Participants were randomised to receive either paracetamol or ibuprofen within the first 28 days of life. The primary outcome was closure or reduction to non-hsPDA, while secondary outcomes included the incidence of short- or medium-term complications of prematurity, such as BPD, NEC, IVH, and ROP. Adverse effects of medications were also reviewed to ensure safety. As part of the pilot design, recruitment, retention and data completeness were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 32 infants were recruited within a 2-year study period. Overall, both groups of infants showed similar baseline characteristics, although ibuprofen group had slightly smaller and sicker infants, despite randomisation. A high proportion of eligible babies were recruited (91.4%) and completed the trial. Post-intervention, 37.5% (16.1\u201350.0%) of infants in the paracetamol group converted to non-hsPDA, compared to 25.0% (7.3\u201352.4%) in the ibuprofen group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.704). There were no statistically significant differences between the two groups in short- or medium-term complications of prematurity or adverse effects. The trial also demonstrated feasibility by achieving the desired sample size in the given time frame with 91% consent and 100% completion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The PAIR (Paracetamol and Ibuprofen Research) trial indicated no differences in efficacy or safety between the two treatments. A larger study is required to validate the findings; this trial has demonstrated the feasibility of such a study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:related-object>\n                      <jats:ext-link>clinicaltrials.gov<\/jats:ext-link>\n                      , identifier NCT04986839.\n                    <\/jats:related-object>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1717284","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:28:24Z","timestamp":1767335304000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Paracetamol or ibuprofen? A pilot study comparing rescue therapy for PDA in preterm infants within the first month"],"prefix":"10.3389","volume":"13","author":[{"given":"Arindam","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupam","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Fullwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Gottstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1111\/bcp.15291","article-title":"Comparative safety and efficacy of paracetamol versus non-steroidal anti-inflammatory agents in neonates with patent ductus arteriosus: a systematic review and meta-analysis of randomized controlled trials","volume":"88","author":"Katsaras","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2025071425","DOI":"10.1542\/peds.2025-071425","article-title":"Committee on fetus and newborn, section on cardiology and cardiac surgery; patent ductus arteriosus in preterm infants","volume":"155","author":"Ambalavanan","year":"2025","journal-title":"Pediatrics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1080\/14767058.2020.1752652","article-title":"Paracetamol for patent ductus arteriosus in preterm infants: a UK national survey","volume":"35","author":"Noureldein","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/archdischild-2020-320207","article-title":"Off-label use of paracetamol in managing patent ductus arteriosus across neonatal intensive care units in the UK","volume":"106","author":"Mukherjee","year":"2020","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/ijpvm.IJPVM_387_19","article-title":"Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study","volume":"12","author":"Shahmirzadi","year":"2021","journal-title":"Int J Prev Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41390-018-0077-x","article-title":"Application of NPE in the assessment of a patent ductus arteriosus","volume":"84","author":"Van Laere","year":"2018","journal-title":"Pediatr Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/adc.2010.204552","article-title":"The pharmacokinetics of intravenous paracetamol in neonates: size matters most","volume":"96","author":"Allegaert","year":"2011","journal-title":"Arch Dis Child"},{"key":"B8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/sj.jp.7211449","article-title":"A new look at bronchopulmonary dysplasia classification","volume":"26","author":"Ryan","year":"2006","journal-title":"J Perinatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0031-3955(16)34975-6","article-title":"Necrotizing enterocolitis: treatment based on staging criteria","volume":"33","author":"Walsh","year":"1986","journal-title":"Pediatr Clin N Am"},{"key":"B10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0022-3476(78)80282-0","article-title":"Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm","volume":"92","author":"Papile","year":"1978","journal-title":"J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00431-016-2830-7","article-title":"Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates","volume":"176","author":"El-Mashad","year":"2017","journal-title":"Eur J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1002\/hsr2.183","article-title":"Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial","volume":"3","author":"Tauber","year":"2020","journal-title":"Health Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"F505","DOI":"10.1136\/archdischild-2013-303816","article-title":"Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3","volume":"98","author":"Sellmer","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJMoa2207418","article-title":"Expectant management or early ibuprofen for patent ductus arteriosus","volume":"388","author":"Hundscheid","year":"2023","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1055\/s-0039-1697672","article-title":"Relationship between duration of infant exposure to a moderate-to- large patent ductus arteriosus shunt and the risk of developing bronchopulmonary dysplasia or death before 36 weeks","volume":"37","author":"Clyman","year":"2020","journal-title":"Am J Perinatol"},{"key":"B16","first-page":"728","article-title":"Ibuprofen and patent ductus arteriosus","volume-title":"N Engl J Med","author":"Clyman","year":"2000"},{"key":"B17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa2305582","article-title":"Trial of selective early treatment of patent ductus arteriosus with ibuprofen","volume":"390","author":"Gupta","year":"2024","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41372-024-02154-4","article-title":"Early drug treatment in preterm patients with large patent ductus arteriosus at 28 weeks or less gestational age: systematic review and meta-analysis","volume":"45","author":"Erzinger","year":"2024","journal-title":"J Perinatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1717284\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:28:25Z","timestamp":1767335305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1717284\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":19,"alternative-id":["10.3389\/fped.2025.1717284"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1717284","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1717284"}}